Program
Anti-PD-1/CD47 Fusion Protein HX009
Also written as “HX009”, “Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection” and “HX009+IN10018”.
Its studies are mostly in Lymphoma · Biliary Tract Neoplasms, led by 2 companies.
Drug pageAnti-PD-1/CD47 Fusion Protein HX009: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hangzhou Hanx Biopharmaceuticalsits history only | 42 open or running | phase 2since May 5, 2021 | May 5, 2021 | Dec 31, 2027phase 2 · NCT06708663 |
| Waterstone Hanxbio Ptyits history only | 10 open or running | phase 1since Aug 28, 2019 | Aug 28, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 28, 2019First study: phase 1 study in Advanced Solid TumorNew to Waterstone Hanxbio PtyWaterstone Hanxbio Pty · NCT04097769 · 21 enrolled · Australia
- May 5, 2021Hangzhou Hanx Biopharmaceuticals’ first study: phase 2 study in Advanced Solid TumorNew to Hangzhou Hanx BiopharmaceuticalsHangzhou Hanx Biopharmaceuticals · NCT04886271 · 20 enrolled · China
- Dec 8, 2021Phase 2 study in LymphomaHangzhou Hanx Biopharmaceuticals · NCT05189093 · 48 enrolled · China
- Jan 29, 2023Phase 1 study in Advanced Solid TumorsHangzhou Hanx Biopharmaceuticals · NCT05731752 · 80 enrolled · China
- Nov 25, 2024Phase 2 study in Biliary Tract NeoplasmsHangzhou Hanx Biopharmaceuticals · NCT06708663 · 124 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Biliary Tract NeoplasmsHangzhou Hanx Biopharmaceuticals · NCT06708663
TargetBeta
“A bispecific antibody fusion protein directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human cell surface antigen CD47, ”NCIt, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06708663Biliary Tract Neoplasms · China | 2 | Recruiting | Hangzhou Hanx Biopharmaceuticals | Dec 31, 2027 | 124 |
| NCT05731752Advanced Solid Tumors · China | 1 | Active, not recruiting | Hangzhou Hanx Biopharmaceuticals | Dec 30, 2024 | 80 |
| NCT05189093Lymphoma · China | 2 | Completed | Hangzhou Hanx Biopharmaceuticals | Jun 25, 2025 | 48 |
| NCT04886271Advanced Solid Tumor · China | 2 | Completed | Hangzhou Hanx Biopharmaceuticals | Jan 12, 2024 | 20 |
| NCT04097769Advanced Solid Tumor · Australia | 1 | Completed | Waterstone Hanxbio Pty | Mar 18, 2021 | 21 |
How it is read
Names in the registry
- “HX009”, 3 entries
- “Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection”, 1 entry
- “HX009+IN10018”, 1 entry
Codes read as this program: HX009.
Conditions, from the studies’ own filings
- Lymphoma, 1 study
- Biliary Tract Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.